PE20250753A1 - Inmunoconjugados de il-2 atenuada-anticuerpo anti-pd-1 y usos de los mismos - Google Patents
Inmunoconjugados de il-2 atenuada-anticuerpo anti-pd-1 y usos de los mismosInfo
- Publication number
- PE20250753A1 PE20250753A1 PE2024002960A PE2024002960A PE20250753A1 PE 20250753 A1 PE20250753 A1 PE 20250753A1 PE 2024002960 A PE2024002960 A PE 2024002960A PE 2024002960 A PE2024002960 A PE 2024002960A PE 20250753 A1 PE20250753 A1 PE 20250753A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- hil
- amino acid
- modified
- antigen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invencion se refiere a proteinas de interleucina-2 humana modificada (hIL-2) que comprenden una sustitucion en el aminoacido 20 seleccionada de D20A, D20S, D20Q, entre otras; en el aminoacido 38 seleccionada de R38E, R38N, R38G, entre otras; en el aminoacido 3 que es T3A; y en el aminoacido 125 que es C125A; las cuales se relacionan a la secuencia no modificada de SEQ ID NO: 345. Dichas proteinas exhiben una reduccion de 1.000 veces en la potencia en el receptor de IL-2 de alta afinidad (hIL-2R-alfa-beta-gamma), de 10.000 veces en la potencia en el receptor de IL-2 de afinidad intermedia (hIL-2R-beta-gamma) y se fusionan con un enlace peptidico al anticuerpo anti-PD-1. Asimismo, refiere a moleculas de anticuerpo humano, o fragmentos de union a antigeno de las mismas, que se unen a la proteina-1 de muerte celular programada humana (hPD-1), y caracterizadas por una region de complementariedad de cadena pesada que comprende una CDR1 seleccionada de SEQ ID NO: 418, CDR2 seleccionada de SEQ ID NO: 419, y CDR3 seleccionada de SEQ ID NO: 420; y una region de complementariedad de cadena ligera que comprende una CDR1 seleccionada de SEQ ID NO: 421, CDR2 seleccionada de SEQ ID NO: 422, y CDR3 seleccionada de SEQ ID NO: 423. Ademas, refiere a inmunoconjugados que comprenden una proteina de interleucina-2 humana (hIL-2) modificada y una molecula de anticuerpo humano, o fragmento de union a antigeno de las mismas. Tambien, menciona una composicion farmaceutica que comprende la proteina hIL-2 modificada; un polinucleotido cuyo acido nucleico codifica dichas proteinas, moleculas de anticuerpo humano, o fragmentos de union a antigenos de las mismas, e inmunoconjugados; un vector que comprende al polinucleotido; una celula modificada que comprende al vector; y metodos para el tratamiento de melanoma y carcinoma de pulmon de celulas no pequenas.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263352842P | 2022-06-16 | 2022-06-16 | |
| US202363481630P | 2023-01-26 | 2023-01-26 | |
| US202363502746P | 2023-05-17 | 2023-05-17 | |
| PCT/US2023/068486 WO2023245097A2 (en) | 2022-06-16 | 2023-06-15 | Anti-pd-1 antibody-attenuated il-2 immunoconjugates and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20250753A1 true PE20250753A1 (es) | 2025-03-13 |
Family
ID=87280228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2024002960A PE20250753A1 (es) | 2022-06-16 | 2023-06-15 | Inmunoconjugados de il-2 atenuada-anticuerpo anti-pd-1 y usos de los mismos |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20240076343A1 (es) |
| EP (1) | EP4540289A2 (es) |
| JP (1) | JP2025520544A (es) |
| KR (1) | KR20250039519A (es) |
| CN (1) | CN119731204A (es) |
| AU (1) | AU2023295521A1 (es) |
| CA (1) | CA3259108A1 (es) |
| CL (1) | CL2024003853A1 (es) |
| IL (1) | IL317511A (es) |
| MX (1) | MX2024015632A (es) |
| PE (1) | PE20250753A1 (es) |
| TW (1) | TW202413442A (es) |
| WO (1) | WO2023245097A2 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025137093A1 (en) * | 2023-12-19 | 2025-06-26 | Cephalon Llc | Uses for attenuated il-2 immunoconjugates |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI82266C (fi) | 1982-10-19 | 1991-02-11 | Cetus Corp | Foerfarande foer framstaellning av il-2 -mutein. |
| WO1985000817A1 (en) | 1983-08-10 | 1985-02-28 | Amgen | Microbial expression of interleukin ii |
| ATE87659T1 (de) | 1986-09-02 | 1993-04-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5837242A (en) | 1992-12-04 | 1998-11-17 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| DZ2788A1 (fr) * | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
| WO2003015697A2 (en) | 2001-08-13 | 2003-02-27 | University Of Southern California | Interleukin-2 mutants with reduced toxicity |
| BR0214650A (pt) | 2001-12-04 | 2005-05-03 | Merck Patent Gmbh | Imunocitoquinas com seletividade modulada |
| MX2007013978A (es) | 2005-05-09 | 2008-02-22 | Ono Pharmaceutical Co | Anticuerpos monoclonales humanos a muerte programada 1 (pd-1) y metodos para tratamiento de cancer utilizando anticuerpos anti-pd-1 solos o en combinacion con otros inmunoterapeuticos. |
| KR101562580B1 (ko) | 2007-06-18 | 2015-10-22 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체 |
| AU2008343589A1 (en) | 2007-12-19 | 2009-07-09 | Centocor Ortho Biotech Inc. | Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods |
| MX340671B (es) | 2011-02-10 | 2016-07-20 | Roche Glycart Ag | Polipeptidos interleuquina- 2 mutantes. |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| EP3559049B1 (en) | 2011-10-28 | 2025-06-11 | Teva Pharmaceuticals Australia Pty Ltd | Polypeptide constructs and uses thereof |
| WO2016164637A1 (en) * | 2015-04-07 | 2016-10-13 | Alector Llc | Anti-sortilin antibodies and methods of use thereof |
| EP3280725B1 (en) | 2016-05-04 | 2020-08-26 | Amgen Inc. | Interleukin-2 muteins for the expansion of t-regulatory cells |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| BR112018076281A2 (pt) | 2016-06-20 | 2019-03-26 | Kymab Limited | imunocitocina, uso de uma imunocitocina, método, composição farmacêutica, método para tratar uma doença proliferativa em um animal, ácido nucleico, vetor, hospedeiro e anticorpo ou fragmento do mesmo |
| CN117024560A (zh) | 2016-12-22 | 2023-11-10 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
| JP7426825B2 (ja) | 2017-04-03 | 2024-02-02 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 抗ｐｄ－１抗体と突然変異ｉｌ－２とまたはｉｌ－１５とのイムノコンジュゲート |
| WO2018189220A1 (en) | 2017-04-13 | 2018-10-18 | F. Hoffmann-La Roche Ag | An interleukin-2 immunoconjugate, a cd40 agonist, and optionally a pd-1 axis binding antagonist for use in methods of treating cancer |
| EP3630163A4 (en) | 2017-05-24 | 2021-06-09 | Pandion Operations, Inc. | Targeted immunotolerance |
| CN111655718B (zh) | 2017-12-19 | 2025-07-22 | Xencor股份有限公司 | 经过工程化的il-2 fc融合蛋白 |
| WO2020247843A2 (en) * | 2019-06-05 | 2020-12-10 | Asher Biotherapeutics, Inc. | Fusions of mutant interleukin-2 polypeptides with antigen binding molecules for modulating immune cell function |
| US20220170028A1 (en) | 2019-06-14 | 2022-06-02 | Cugene Inc | Novel interleukin-2 variants and bifunctional fusion molecules thereof |
| TW202128961A (zh) * | 2019-11-20 | 2021-08-01 | 美商安維塔生物科學股份有限公司 | 細胞激素融合蛋白及其醫藥組合物及治療應用 |
| EP4073094A1 (en) | 2019-12-12 | 2022-10-19 | Iltoo Pharma | Interleukin 2 chimeric constructs |
| CN115698052A (zh) | 2020-03-19 | 2023-02-03 | 信达生物制药(苏州)有限公司 | 白介素2突变体及其用途 |
| CN118271419A (zh) * | 2020-03-31 | 2024-07-02 | 韩美药品株式会社 | 新型免疫刺激il-2类似物 |
| US11897930B2 (en) * | 2020-04-28 | 2024-02-13 | Anwita Biosciences, Inc. | Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications |
| US20230226203A1 (en) * | 2020-06-18 | 2023-07-20 | Proviva Therapeutics (Hong Kong) Limited | Activatable procytokines |
| MX2022016532A (es) | 2020-07-02 | 2023-04-12 | Inhibrx Inc | Polipeptidos que comprenden polipeptidos de il-2 modificados y usos de los mismos. |
| WO2022048640A1 (zh) * | 2020-09-04 | 2022-03-10 | 江苏先声药业有限公司 | Il-2突变体及其应用 |
| US11865082B2 (en) | 2020-09-09 | 2024-01-09 | Hoffmann-La Roche Inc. | Combination therapy of PD-1-targeted IL-2 variant immunocytokines and antibodies against human PD-L1 |
| CN116761883A (zh) | 2021-01-19 | 2023-09-15 | 塞内卡治疗公司 | 武装的塞尼卡谷病毒溶瘤性治疗组合物及其方法 |
| EP4314033A4 (en) | 2021-03-31 | 2025-04-23 | Anwita Biosciences, Inc. | FUSION PROTEINS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC APPLICATIONS |
-
2023
- 2023-06-15 TW TW112122315A patent/TW202413442A/zh unknown
- 2023-06-15 JP JP2024573944A patent/JP2025520544A/ja active Pending
- 2023-06-15 US US18/335,650 patent/US20240076343A1/en active Pending
- 2023-06-15 AU AU2023295521A patent/AU2023295521A1/en active Pending
- 2023-06-15 WO PCT/US2023/068486 patent/WO2023245097A2/en not_active Ceased
- 2023-06-15 PE PE2024002960A patent/PE20250753A1/es unknown
- 2023-06-15 IL IL317511A patent/IL317511A/en unknown
- 2023-06-15 CN CN202380047535.1A patent/CN119731204A/zh active Pending
- 2023-06-15 KR KR1020257000352A patent/KR20250039519A/ko active Pending
- 2023-06-15 EP EP23741552.6A patent/EP4540289A2/en active Pending
- 2023-06-15 CA CA3259108A patent/CA3259108A1/en active Pending
-
2024
- 2024-09-03 US US18/823,422 patent/US12281148B2/en active Active
- 2024-12-13 MX MX2024015632A patent/MX2024015632A/es unknown
- 2024-12-16 CL CL2024003853A patent/CL2024003853A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20240425562A1 (en) | 2024-12-26 |
| IL317511A (en) | 2025-02-01 |
| WO2023245097A2 (en) | 2023-12-21 |
| WO2023245097A3 (en) | 2024-02-01 |
| KR20250039519A (ko) | 2025-03-20 |
| EP4540289A2 (en) | 2025-04-23 |
| CA3259108A1 (en) | 2023-12-21 |
| AU2023295521A1 (en) | 2025-01-02 |
| MX2024015632A (es) | 2025-02-10 |
| TW202413442A (zh) | 2024-04-01 |
| US12281148B2 (en) | 2025-04-22 |
| JP2025520544A (ja) | 2025-07-03 |
| US20240076343A1 (en) | 2024-03-07 |
| CN119731204A (zh) | 2025-03-28 |
| CL2024003853A1 (es) | 2025-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Reiter et al. | Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv | |
| US11236150B2 (en) | Hetero-dimeric multi-specific antibody format | |
| ES2693596T3 (es) | Anticuerpo que se une a CD3 humano | |
| BRPI0715660B8 (pt) | anticorpo isolado que se liga a il-31 humana, e, uso de um anticorpo monoclonal | |
| PE20230408A1 (es) | Anticuerpo anti-lilrb1 y usos del mismo | |
| ES3015105T3 (en) | Anti-cd3 epsilon antibodies | |
| PE20231851A1 (es) | Proteinas que se unen a nkg2d, cd16 y clec12a | |
| JP2020504087A (ja) | ４−１ｂｂ結合タンパク質及びその使用 | |
| PE20091449A1 (es) | Proteinas de union a antigenos | |
| KR20150080033A (ko) | 골관절염 및 통증의 치료 방법 | |
| PE20210554A1 (es) | Anticuerpos anti-cxcr5 y composiciones y usos de los mismos | |
| CY1110848T1 (el) | Αντισωμα αντι ανθρωπου νοgo α kai h φαρμακευτικη του χρηση | |
| JP2019506140A5 (es) | ||
| JP2019505565A5 (es) | ||
| US11945863B2 (en) | CD33-, CD16- and CD123-specific single chain triplebody | |
| PE20250753A1 (es) | Inmunoconjugados de il-2 atenuada-anticuerpo anti-pd-1 y usos de los mismos | |
| RU2380377C2 (ru) | Nogo-A-СВЯЗЫВАЮЩИЕ МОЛЕКУЛЫ И ИХ ФАРМАЦЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ | |
| CN120882747A (zh) | 一种抗gprc5d纳米抗体及其应用 | |
| AR129638A1 (es) | Inmunoconjugados de anticuerpo anti-pd-1-il-2 atenuada y usos de los mismos | |
| Collins et al. | Bispecific FpFs: a versatile tool for preclinical antibody development | |
| WO2025005224A1 (ja) | Ｈｅｒ２分解活性を有する抗体軽鎖由来のポリペプチド、前記ポリペプチドを含むｈｅｒ２結合ポリペプチド、これらの製造法及びこれらの用途 | |
| RU2024116415A (ru) | Композиции, содержащие улучшенные мультиспецифические связывающие агенты для иммунного ответа | |
| TW202426499A (zh) | 具有pH依賴性的抗CTLA4抗體或抗原結合片段 | |
| AR129642A1 (es) | Variantes il-12, anticuerpos anti-pd1, proteínas de fusión y usos de estos | |
| HK40057046A (en) | An anti-clta4 monoclonal antibody or antigen binding fragment thereof, a pharmaceutical composition and use |